ascopubs.org

Palbociclib (PAL) + letrozole (L) as first-line (1L) therapy (tx) in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) advanced ...

Visceral 19.3 (16.4-22.2) 12.9 (8.4-16.6) 0.63 (0.47-0.85).0011 Liver 13.7 (10.9-16.6) 8.4 (5.5-12.9) 0.62 (0.41-0.95).0255 Lung 22.2 (16.8-25.4) 13.6 (8.4-18.5) 0.59 (0.41-0.83).0025 Visceral and ...
ascopubs.org

Impact of prior anticancer treatments on palbociclib (PAL) clinical outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+ ...

Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study. BLU-222, an ...